The latest IBRX analyst rating update shows Piper Sandler maintained an Overweight view on ImmunityBio, Inc. (IBRX) on March 04, 2026. Piper Sandler also raised its price target to $12, signaling continued conviction in the company’s clinical and commercial prospects. The note arrives as shares moved, with a reported -10.2% (-$1.02) price change since the communication. This IBRX analyst rating keeps the firm in the more favorable tier of coverage and gives investors a clear reference point for valuation and risk assessment.

IBRX analyst rating: Piper Sandler Maintains Overweight on March 04, 2026

Piper Sandler on March 04, 2026 maintained Overweight for ImmunityBio, Inc. and raised its price target to $12. The firm’s published note is available via StreetInsider for direct review source. This action communicates steady conviction rather than a directional upgrade or downgrade, keeping IBRX in a favored coverage bucket.

IBRX analyst rating: What the $12 price target implies

A $12 price target sets a benchmark for investor expectations and frames upside relative to current trading levels. Piper Sandler’s PT reflects assumptions about clinical progress and potential commercialization pathways for ImmunityBio programs, and gives investors a quantified valuation reference when comparing peers or modeling scenarios.

IBRX analyst rating: Implications for investors and risk

Maintaining Overweight means Piper Sandler expects relative outperformance versus the analyst coverage universe, but investors must weigh this against clinical and execution risk. The IBRX analyst rating signals confidence, yet investors should track trial readouts, regulatory milestones, and cash runway as key risk drivers before increasing exposure.

IBRX analyst rating: Stock performance and market context

ImmunityBio’s market capitalization is $9,232,427,791, and the stock showed a -10.2% (-$1.02) move since the note data point. Recent corporate events include the Q4 2025 earnings call and company updates, which give context to the analyst view source. Price moves show the market is already pricing some disappointment or re-weighting risk versus Piper Sandler’s maintained optimism.

IBRX analyst rating: Historical coverage and analyst landscape

This update lists Piper Sandler as the reporting firm, making it the primary named analyst action for this cycle. Historically, IBRX has had episodic coverage from a mix of boutique and bank analysts; this single-firm note underscores that coverage can be concentrated, so investors should monitor additional checks from other firms to build a broader consensus.

IBRX analyst rating: Meyka analysis and grading

Meyka AI rates IBRX with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade is a snapshot used to guide comparative analysis and is not a guarantee; we are not financial advisors.

Final Thoughts

Piper Sandler’s decision to maintain Overweight on ImmunityBio on March 04, 2026 and to lift the price target to $12 leaves a clear signal for investors: the firm expects relative outperformance, but expects progress rather than a sudden change in outlook. The IBRX analyst rating provides a valuation anchor as shareholders weigh ongoing trial results and operational milestones. With a market cap of $9,232,427,791 and a reported -10.2% (-$1.02) move tied to recent commentary, investors should treat the Piper Sandler view as one informed input among many. Our Meyka AI-powered market analysis platform notes concentrated analyst coverage and recommends tracking further independent notes and company disclosures. Remember, Meyka AI rates IBRX with a grade of B+, and that grade reflects relative positioning, growth metrics, and consensus; it is not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.